Focinvez Patent Expiration

Focinvez is a drug owned by Steriscience Pte Ltd. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 11, 2039. Details of Focinvez's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065256 Administration and dosage of diaminophenothiazines
Jan, 2039

(14 years from now)

Active
US12042504 Injectable fosaprepitant composition
Jan, 2039

(14 years from now)

Active
US11065265 Compositions of fosaprepitant and methods of preparation
Jan, 2039

(14 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Focinvez's patents.

Given below is the list of recent legal activities going on the following patents of Focinvez.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 20 Jul, 2021 US11065256
Recordation of Patent Grant Mailed 20 Jul, 2021 US11065265
Patent Issue Date Used in PTA Calculation 20 Jul, 2021 US11065256
Patent Issue Date Used in PTA Calculation 20 Jul, 2021 US11065265
Email Notification 01 Jul, 2021 US11065265
Email Notification 01 Jul, 2021 US11065256
Issue Notification Mailed 30 Jun, 2021 US11065265
Issue Notification Mailed 30 Jun, 2021 US11065256
Mail Response to 312 Amendment (PTO-271) 25 Jun, 2021 US11065256
Email Notification 25 Jun, 2021 US11065256

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Focinvez is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Focinvez's family patents as well as insights into ongoing legal events on those patents.

Focinvez's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Focinvez's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 11, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Focinvez Generics:

Fosaprepitant Dimeglumine is the generic name for the brand Focinvez. 18 different companies have already filed for the generic of Focinvez, with Mylan Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Focinvez's generic

Alternative Brands for Focinvez

There are several other brand drugs using the same active ingredient (Fosaprepitant Dimeglumine) as Focinvez. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Merck And Co Inc
Emend


Apart from brand drugs containing the same ingredient, some generics have also been filed for Fosaprepitant Dimeglumine, Focinvez's active ingredient. Check the complete list of approved generic manufacturers for Focinvez





About Focinvez

Focinvez is a drug owned by Steriscience Pte Ltd. Focinvez uses Fosaprepitant Dimeglumine as an active ingredient. Focinvez was launched by Steriscience in 2023.

Approval Date:

Focinvez was approved by FDA for market use on 22 August, 2023.

Active Ingredient:

Focinvez uses Fosaprepitant Dimeglumine as the active ingredient. Check out other Drugs and Companies using Fosaprepitant Dimeglumine ingredient

Dosage:

Focinvez is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 150MG BASE/50ML (EQ 3MG BASE/ML) SOLUTION Prescription INTRAVENOUS